Pharmaceutical Technology1mon
PEP-010 by PEP-Therapy for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
PEP-010 is under clinical development by PEP-Therapy and currently in Phase I for Pancreatic Ductal Adenocarcinoma. According to GlobalData, Phase I drugs for Pancreatic Ductal Adenocarcinoma does not ...
Pharmaceutical Technology1mon
PEP-010 by PEP-Therapy for Metastatic Ovarian Cancer: Likelihood of Approval
PEP-010 is under clinical development by PEP-Therapy and currently in Phase I for Metastatic Ovarian Cancer. According to GlobalData, Phase I drugs for Metastatic Ovarian Cancer have a 77% phase ...
snmjournals.org3y
Radiosynthesis of [90Y]DOTA-DUPA-Pep for clinical applications
Aiming at therapy, we continued with the new ligand DUPA-Pep based ... The quality control showed no free 90YCl3 (Rt: 1.3min) and ≥98% radiochemical purity for [90Y]DOTA-DUPA-Pep (Rt: 4.8min).The ...
Cystic Fibrosis Foundation3y
Positive Expiratory Pressure
It also holds your airways open, keeping them from closing. Although your respiratory therapist may suggest a different way to use PEP based on your unique circumstances, typically, people perform 10 ...
Medscape1mon
Advances in Airway Clearance Technologies for Chronic Obstructive Pulmonary Disease
For example, combining a PEP device with nebulized medications means medication is inhaled on each inspiration while sputum clearance is promoted on each expiration. Reducing therapy time can be ...